Hong Kong stock anomaly | CRO concept stocks collectively opened lower, with the Pharmaron group leading the decline. The US Senate version of the "Biological Safety Act" hearing was approved.
Concept stocks related to CRO collectively opened lower, with WUXI APPTEC leading the decline. As of the time of publication, WUXI APPTEC fell by 14.92% to HKD 48.2, PHARMARON dropped by 7.17% to HKD 10.36, TIGERMED decreased by 5.21% to HKD 25.45, and Asymchem declined by 3.89% to HKD 69.1. On the news front, the U.S. Senate Homeland Security Committee held a proposal hearing, and the Senate version of the "Biological Safety Act" (S.3558) was passed by a vote of 11-1. This means that the "Biological Safety Act" (S.3558) has officially passed the "second reading" and is set to proceed to the Senate for the "third reading." According to a reputable U.S. website's forecast, the probability of the bill being enacted has increased from the previous 18% to the current 23%. Experts suggest that "it will undoubtedly impact stock prices in the short term, but the bill is still far from being enacted," indicating that there may be other variables to consider in the future. In addition, the House bill H.R.7085 will also hold a hearing in the House of Representatives at 9 a.m. local time on March 7th.
Zhitong App learned that the concept stocks of CRO collectively opened lower, with the Pharmaron group leading the decline. As of the time of publication, WUXI APPTEC (02359) fell by 14.92% to HKD 48.2; PHARMARON (03759) fell by 7.17% to HKD 10.36; TIGERMED (03347) fell by 5.21% to HKD 25.45; Asymchem (06821) fell by 3.89% to HKD 69.1.
On the news front, the U.S. Senate Homeland Security Committee held a proposal hearing, and the Senate version of the "Biological Safety Act" (S.3558) was passed by a vote of 11-1. This means that the "Biological Safety Act" (S.3558) has officially passed the "second reading" and is set to enter the Senate for the "third reading." According to a reputable U.S. website's forecast, the probability of the bill being enacted has increased from the previous 18% to the current 23%.
Experts have stated, "Undoubtedly, this will impact corporate stock prices in the short term, but the bill is still far from actual legislation." This implies that whether there will be other variables in the subsequent process remains to be seen. In addition, the House bill H.R.7085 will also hold a hearing in the House of Representatives at 9 a.m. local time on March 7th.